WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the ...

The stock options were granted to the new employees on their respective hire dates (October 7, 2024, and October 14, 2024) with an exercise price equal to the closing price of the company’s common ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

GSK said that both the Anchor-1 and Anchor-2 trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score after 52 weeks, as well as a change in mean nasal ...

GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic ...

LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, ...

Cerebral venous sinus thrombosis (CVST ... Symptoms include nausea, seizures, severe focal neurological deficits, coma, and headache (the most common presenting symptom). Anticoagulation is ...

Seek emergency care if your symptoms include eye swelling, vision changes, severe headache, neck stiffness, or fever. Nasal congestion occurs when tissue lining the nose swells because of inflamed ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

Father Warren worked for the railroad and as was common in those days, her mother Clara was home with all the children. With ...

Symptoms of sinusitis (fever, cough, nasal obstruction, nasal secretion and headache) were assessed at baseline and at follow-up visits, and classified as 'absent', 'mild' or 'severe' by the ...